Title:
CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS TARGETING ALK
Document Type and Number:
WIPO Patent Application WO/2020/241827
Kind Code:
A1
Abstract:
A problem addressed by the present invention is to develop a chimeric antigen receptor (CAR) effective against solid tumors that express anaplastic lymphoma kinase (ALK). The present invention provides a polynucleotide encoding a CAR protein having a target-binding domain that binds to an extracellular ligand binding region of ALK, a transmembrane domain, and an intracellular signal transduction domain, wherein the target-binding domain is selected from FAM150A, FAM150B, and fragments thereof that bind to the extracellular ligand binding region of ALK, and a genetically modified cell into which the polynucleotide has been introduced.
Inventors:
NAKAZAWA YOZO (JP)
SAITO SHOJI (JP)
YAGYU SHIGEKI (JP)
NAKANO SHIGERU (JP)
MOMOSE TAKAKI (JP)
HITOMI KENTA (JP)
SAITO SHOJI (JP)
YAGYU SHIGEKI (JP)
NAKANO SHIGERU (JP)
MOMOSE TAKAKI (JP)
HITOMI KENTA (JP)
Application Number:
PCT/JP2020/021348
Publication Date:
December 03, 2020
Filing Date:
May 29, 2020
Export Citation:
Assignee:
KISSEI PHARMACEUTICAL (JP)
UNIV SHINSHU (JP)
KYOTO PREFECTURAL PUBLIC UNIV CORP (JP)
UNIV SHINSHU (JP)
KYOTO PREFECTURAL PUBLIC UNIV CORP (JP)
International Classes:
C12N15/62
Domestic Patent References:
| WO2015069922A2 | 2015-05-14 | |||
| WO2015069922A2 | 2015-05-14 | |||
| WO2018052142A1 | 2018-03-22 |
Foreign References:
| JP2019103074A | 2019-06-24 |
Other References:
RESHETNYAK A. V. ET AL.: "Augmentor alpha and (3 (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand- receptor interactions", PNAS, vol. 112, no. 52, 2015, pages 15862 - 15867, XP055764923
GUAN, J. ET AL.: "FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase", ELIFE, vol. 4, no. e09811, 2015, pages 1 - 16, XP055764931
RESHETNYAK, A. V. ET AL.: "Identification of a biologically active fragment of ALK and LTK-ligand 2(augmentor-alpha", PNAS, vol. 115, no. 33, 2018, pages 8340 - 8345, XP055764936
WALKER, A. J. ET AL.: "Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase", MOLECULAR THERAPY, vol. 25, no. 9, 2017, pages 2189 - 2201, XP055568995, DOI: 10.1016/j.ymthe.2017.06.008
NAT. REV. CANCER, vol. 13, 2013, pages 685 - 700
ONCOTARGET, vol. 8, no. 64, 2017, pages 107513 - 107529
COLD SPRING HARB. MOL. CASE STUD., vol. 3, 2017, pages a001115
MOLECULAR THERAPY, vol. 25, no. 9, 2017, pages 2189 - 2201
PNAS, vol. 111, no. 44, 2014, pages 15741 - 15745
ELIFE, vol. 4, 2015, pages e09811
PNAS, vol. 112, no. 52, 2015, pages 15862 - 15867
PNAS, vol. 115, no. 33, 2018, pages 8340 - 8345
"NCBI", Database accession no. NM_001002919.2
"Uniprot", Database accession no. Q6UX46-1
"GenBank", Database accession no. U03397.1
ONCOIMMUNOLOGY, vol. 5, no. 12, 2016, pages e1253656
HUANG XGUO H ET AL., MOL. THER., vol. 16, 2008, pages 580 - 9
SINGH HMANURI PR ET AL., CANCER RES., vol. 68, 2008, pages 2961 - 71
DENIGER DCYU J ET AL., PLOS ONE, vol. 10, 2015, pages e0128151
SINGH HMOYES JS ET AL., CANCER GENE THER., vol. 22, 2015, pages 95 - 100
HOU XDU Y ET AL., CANCER BIOL. THER., vol. 16, 2015, pages 8 - 16
SINGH HHULS H ET AL., IMMUNOL. REV., vol. 257, 2014, pages 181 - 90
NAKAZAWA YSAHA S ET AL., J. IMMUNOTHER., vol. 36, 2013, pages 112 - 10
NAKAZAWA YHUYE LE ET AL., J. IMMUNOTHER., vol. 32, 2009, pages 826 - 36
GALVAN DLNAKAZAWA Y ET AL., J IMMUNOTHER., vol. 32, 2009, pages 837 - 44
HUYE LENAKAZAWA Y ET AL., MOL. THER., vol. 19, 2011, pages 2239 - 48
SAHA SNAKAZAWA Y ET AL., J. VIS. EXP., no. 69, 2012, pages e4235
SAITO SNAKAZAWA Y ET AL., CYTOTHERAPY, vol. 16, 2014, pages 1257 - 69
NAKAZAWA ET AL., JOURNAL OF HEMATOLOGY &ONCOLOGY, vol. 9, 2016, pages 27
YANG XU ET AL., BLOOD, vol. 123, 2014, pages 3750 - 3759
See also references of EP 3978611A4
GUAN, J. ET AL.: "FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase", ELIFE, vol. 4, no. e09811, 2015, pages 1 - 16, XP055764931
RESHETNYAK, A. V. ET AL.: "Identification of a biologically active fragment of ALK and LTK-ligand 2(augmentor-alpha", PNAS, vol. 115, no. 33, 2018, pages 8340 - 8345, XP055764936
WALKER, A. J. ET AL.: "Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase", MOLECULAR THERAPY, vol. 25, no. 9, 2017, pages 2189 - 2201, XP055568995, DOI: 10.1016/j.ymthe.2017.06.008
NAT. REV. CANCER, vol. 13, 2013, pages 685 - 700
ONCOTARGET, vol. 8, no. 64, 2017, pages 107513 - 107529
COLD SPRING HARB. MOL. CASE STUD., vol. 3, 2017, pages a001115
MOLECULAR THERAPY, vol. 25, no. 9, 2017, pages 2189 - 2201
PNAS, vol. 111, no. 44, 2014, pages 15741 - 15745
ELIFE, vol. 4, 2015, pages e09811
PNAS, vol. 112, no. 52, 2015, pages 15862 - 15867
PNAS, vol. 115, no. 33, 2018, pages 8340 - 8345
"NCBI", Database accession no. NM_001002919.2
"Uniprot", Database accession no. Q6UX46-1
"GenBank", Database accession no. U03397.1
ONCOIMMUNOLOGY, vol. 5, no. 12, 2016, pages e1253656
HUANG XGUO H ET AL., MOL. THER., vol. 16, 2008, pages 580 - 9
SINGH HMANURI PR ET AL., CANCER RES., vol. 68, 2008, pages 2961 - 71
DENIGER DCYU J ET AL., PLOS ONE, vol. 10, 2015, pages e0128151
SINGH HMOYES JS ET AL., CANCER GENE THER., vol. 22, 2015, pages 95 - 100
HOU XDU Y ET AL., CANCER BIOL. THER., vol. 16, 2015, pages 8 - 16
SINGH HHULS H ET AL., IMMUNOL. REV., vol. 257, 2014, pages 181 - 90
NAKAZAWA YSAHA S ET AL., J. IMMUNOTHER., vol. 36, 2013, pages 112 - 10
NAKAZAWA YHUYE LE ET AL., J. IMMUNOTHER., vol. 32, 2009, pages 826 - 36
GALVAN DLNAKAZAWA Y ET AL., J IMMUNOTHER., vol. 32, 2009, pages 837 - 44
HUYE LENAKAZAWA Y ET AL., MOL. THER., vol. 19, 2011, pages 2239 - 48
SAHA SNAKAZAWA Y ET AL., J. VIS. EXP., no. 69, 2012, pages e4235
SAITO SNAKAZAWA Y ET AL., CYTOTHERAPY, vol. 16, 2014, pages 1257 - 69
NAKAZAWA ET AL., JOURNAL OF HEMATOLOGY &ONCOLOGY, vol. 9, 2016, pages 27
YANG XU ET AL., BLOOD, vol. 123, 2014, pages 3750 - 3759
See also references of EP 3978611A4
Attorney, Agent or Firm:
HIRAKI & ASSOCIATES (JP)
Download PDF: